ClinicalTrials.gg
RecruitingNCT07220512Updated Jul 15, 2026

The Better, Harder, Faster, Stronger Study

An observational study in Frailty at Older Adults, Ovarian Cancer and Endometrial Cancer, sponsored by Wake Forest University Health Sciences. Recruiting at 1 site in United States. Open to female participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Wake Forest University Health Sciences · Observational

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
35
Ages
55 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Ovarian Neoplasms by Wake Forest University Health Sciences — 1 open to participants now, 1 under way, none of them phase 3. Ovarian Neoplasms · Wake Forest University Health Sciences.

Started
2025
the only one that year
Observational
2 of 10
1 open now
Registered
10th of 10
by date

Among the 10 studies in Ovarian Neoplasms by Wake Forest University Health Sciences, this one is the only one that started in 2025, is one of 2 observational ones, and was the 10th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

1 of the 10 studies in Ovarian Neoplasms by Wake Forest University Health Sciences is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 55 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Ovarian Neoplasms by Wake Forest University Health Sciences, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate changes in the electronic Frailty Index (eFI) score following 3-4 cycles of neoadjuvant chemotherapy (NACT) in participants with advanced ovarian and endometrial cancer.

Read the detailed description

This observation study is designed investigate changes in frailty and cognitive function in participants with advanced ovarian and endometrial cancer before and after undergoing NACT.

Changes in frailty and cognitive function will be measured using the eFI which is an automated EMR-based tool based that uses a combination of clinical encounters, diagnosis codes, laboratory workups, and Medicare annual wellness visit data as markers of frailty status.

Participants with either ovarian/primary peritoneal/fallopian tube carcinoma or endometrial carcinoma will be approached for interest in participating in this study.

Prior to the first prechemotherapy appointment, eFI will be collected as well as PROs (Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog), Patient Health Questionnaire-2 and MoCA (Montreal Cognitive Assessment)) and historical data.

After 3-4 rounds of NACT, eFI, FACT-Cog and MoCA will be collected again. Data on intra-operative and post-operative complications will be collected after surgery.

03

Conditions studied

  • Frailty at Older Adults
  • Ovarian Cancer
  • Endometrial Cancer
  • Cognitive Dysfunction
  • Neoadjuvant Chemotherapy

Keywords

  • Frailty
  • ovarian cancer
  • endometrial cancer
  • cognitive dysfunction
  • neoadjuvant chemotherapy
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients 55 or older seen in clinic with either ovarian/primary peritoneal/fallopian tube carcinoma or endometrial carcinoma who are planned for NACT

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to understand and willingness to sign an IRB-approved .
  • Age > 55 years at the time of enrollment.
  • Newly diagnosed suspected ovarian/primary peritoneal/fallopian tube carcinoma of any histological subtype, FIGO Stage II-IV, per enrolling investigator, or newly diagnosed suspected endometrial carcinoma of any histologic subtype, FIGO Stage II-IV, per enrolling investigator.
  • Planned for 3 or 4 cycles of NACT, with interval cytoreductive surgery planned thereafter.
  • Ability to read, understand, and write the English language.
  • As determined by the enrolling investigator, ability of the participant to understand and comply with study procedures for the entire length of the study.

Exclusion criteria

Exclusion Criteria:

  • History of .
  • History of poorly controlled psychiatric conditions, defined as hospitalization within the prior 3 months for psychiatric disorders, traumatic brain injury, cerebrovascular event, or dementia, per the enrolling investigator.
  • Use of anti-amyloid agents, cholinesterase inhibitors, or Memantine for Alzheimers/cognitive impairment, at the time of enrollment.
  • Vision impairment that would impede completion of study assessments, per enrolling investigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
35 participants (estimated)
Patient registry
No

Groups and cohorts

  • Participants with ovarian or endometrial carcinoma with planned NACT.

    Participants over 55 years old with either ovarian/primary peritoneal/fallopian tube carcinoma or endometrial carcinoma

    Other: data collection

Interventions

  • Otherdata collection

    PROs, historical and longitudinal data collection and eFI calculation

06

What researchers measure

Primary outcomes

  1. Change in electronic frailty index (eFI)

    eFI is an automated electronic medical record-based tool based on a deficit accumulation model of frailty that uses a combination of clinical encounters, diagnosis codes, laboratory workups, and Medicare annual wellness visit data as markers of frailty status.

    Time frame: From pre- Neoadjuvant Chemotherapy (NACT; no later than 60 days after consent) to post-NACT (no later than 30 days after completion of the last cycle of NACT)

Secondary outcomes

  1. Change in proportion of participants in the fit/pre-frail (eFI score ≤ 0.21) versus frail category (eFi score > 0.21)

    eFI scores are categorized into fit/pre-frail and frail category using the cut of point 0.21

    Time frame: Before and after NACT - At visit 1, no later than 60 days after consent and no later than 30 days after completion of the last cycle of NACT.

  2. Prevalence of cognitive dysfunction

    A MoCA score of 25 or less is used to define cognitive dysfunction

    Time frame: Before NACT - At visit 1, no later than 60 days after consent

  3. Prevalence of patient-reported cognitive dysfunction

    A FACT-Cog PCI score of less than 54 is used to define cognitive dysfunction

    Time frame: Before NACT - At visit 1, no later than 60 days after consent

  4. Changes in cognitive function as measured by MoCA

    Changes in cognitive function are calculated based on changes in MoCA before and after NACT

    Time frame: Before NACT - At visit 1, no later than 60 days after consent and Post-NACT - no later than 30 days after completion of the last cycle of NACT

  5. Changes in cognitive function as measured by FACT-Cog PCI

    Changes in cognitive function are calculated based on changes in FACT-Cog PCI score before and after NACT

    Time frame: Before NACT - At visit 1, no later than 60 days after consent and Post-NACT - no later than 30 days after completion of the last cycle of NACT

  6. Prevalence of mood disorder

    Defined as a PHQ-2 score of 3 or greater

    Time frame: Before NACT - At visit 1, no later than 60 days after consent

Other outcomes

  1. Length of hospital stay

    Length of hospital stay

    Time frame: Post-NACT - no later than 30 days after completion of the last cycle of NACT

  2. Surgical complication

    Surgical complication is coded as 0 if no complications occurred, and 1 if any of the complications listed in the NSQIP surgical complication list were present (https://cdn-links.lww.com/permalink/aa/d/aa\_2020\_05\_21\_freundlich\_aa-d-19-02104r1\_sdc1.pdf).

    Time frame: Post-NACT - no later than 30 days after completion of the last cycle of NACT

  3. Discharge disposition home vs. rehabilitation facility

    A binary variable indicating discharge disposition: home (0) vs. rehabilitation facility (1).

    Time frame: Post-NACT - no later than 30 days after completion of the last cycle of NACT

  4. Screening rate

    Screening rate is defined as the proportion of individuals who are potentially eligible, per EMR review, and are willing to be enrolled, out of the total number of participants approached for screening.

    Time frame: at screening

  5. Retention rate

    Retention rate will be defined as the proportion of enrolled participants who completed all required study procedures out of the total number of participants who were initially enrolled.

    Time frame: Post-NACT - no later than 30 days after completion of the last cycle of NACT

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Nov 2026, 16 months after the start.

Of 216 non-industry observational studies under Ovarian Neoplasms, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 206. This study's planned 16 months is below that.

Counting every sponsor, half of 268 studies reached it within 61 months; a quarter within 35 and three quarters within 185.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2025
First posted
Oct 24, 2025
StartActual
Jul 28, 2025
Primary completionEst.
Nov 2026
CompletionEst.
May 2027
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07220512
Collaborators
Atrium Health Wake Forest Baptist
Responsible party
Sponsor
First posted
Oct 24, 2025
Start date
Jul 28, 2025
Primary completion
Nov 2026 (estimated)
Completion
May 2027 (estimated)
Last update
Jul 15, 2026

Study contacts

Sydney McEntire, RN
Contact
sydney.mcentire@advocatehealth.org
336-713-5879
Anna Kuan-Celarier, MD
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion